Looking at the info provided by Lilly:

Preparation and Administration
• The 700 mg dose MUST BE prepared using 0.9% sodium chloride.
• Preparation of 700 mg dose of bamlanivimab for IV infusion*
• Administration of a dose of 700 mg of bamlanivimab in an IV infusion*
• Bamlanivimab solution for infusion should be prepared by a qualified health care professional using aseptic technique.

Hello!

Our institution has started a discussion around what PPE and preparation precautions should be in place for monoclonal antibodies (in both the inpatient and ambulatory setting). We recognize that the only monoclonal antibodies that fall on the NIOSH hazardous drug list include those that are conjugated to an antineoplastic (eg, gemtuzumab)... whereas other commonly used mAbs (eg, infliximab, omalizumab-outpatient) are not present in the list. (I did attach two articles that leaned towards treating these agents as hazardous medications.)